We are live on ! Find out more
GC

Guggenheim Capital Portfolio holdings

AUM $12.9B
1-Year Est. Return 27.3%
This Fund
S&P 500
This Quarter Est. Return
+4.41%
1 Year Est. Return
+27.3%
3 Year Est. Return
+83.37%
5 Year Est. Return
+104.66%
10 Year Est. Return
+359.15%
AUM
$42.6B
AUM Growth
+$4.82B
Cap. Flow
+$3.68B
Cap. Flow %
8.65%
Top 10 Hldgs %
12.95%
Holding
2,932
New
107
Increased
1,463
Reduced
1,212
Closed
134

Sector Composition

Rank Sector Weight
1 Technology 12.83%
2 Financials 12.17%
3 Healthcare 10.88%
4 Industrials 10.2%
5 Consumer Discretionary 9.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NWY
2726
DELISTED
New York & Co Inc
NWY
$29K ﹤0.01%
13,971
-5
-0% -$8
VALE.P
2727
DELISTED
Vale S A
VALE.P
$29K ﹤0.01%
3,110
-174,542
-98% -$1.64M
UTSI icon
2728
UTStarcom
UTSI
$23.5M
$28K ﹤0.01%
2,968
-4
-0.1% -$35
UQM
2729
DELISTED
UQM Technologies, Inc.
UQM
$27K ﹤0.01%
23,224
+258
+1% +$238
PLX icon
2730
Protalix BioTherapeutics
PLX
$187M
$26K ﹤0.01%
4,515
+451
+11% +$2.89K
ALIM
2731
DELISTED
Alimera Sciences
ALIM
$26K ﹤0.01%
1,266
+2
+0.2% +$43
GALT icon
2732
Galectin Therapeutics
GALT
$200M
$25K ﹤0.01%
11,688
-21
-0.2% -$42
ALR
2733
DELISTED
AlerisLife Inc
ALR
$25K ﹤0.01%
1,586
+1
+0.1% +$16
UBP
2734
DELISTED
Urstadt Biddle Properties Inc.
UBP
$24K ﹤0.01%
1,343
+9
+0.7% +$157
ROYT
2735
DELISTED
PACIFIC COAST OIL TRUST
ROYT
$24K ﹤0.01%
14,883
+501
+3% +$809
GROW icon
2736
US Global Investors
GROW
$37M
$23K ﹤0.01%
10,768
-27
-0.3% -$40
GSAT icon
2737
Globalstar
GSAT
$10.8B
$23K ﹤0.01%
939
+11
+1% +$318
SRRA
2738
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$23K ﹤0.01%
+375
New +$22K
ARQL
2739
DELISTED
Arqule Inc
ARQL
$23K ﹤0.01%
21,092
+6,343
+43% +$7.3K
NAVB
2740
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$23K ﹤0.01%
2,806
+139
+5% +$1.18K
RAS
2741
DELISTED
RAIT Financial Trust
RAS
$23K ﹤0.01%
+31,605
New +$41.5K
LUNA
2742
DELISTED
Luna Innovations Incorporated
LUNA
$23K ﹤0.01%
13,522
+292
+2% +$427
SPHS
2743
DELISTED
Sophiris Bio, Inc.
SPHS
$23K ﹤0.01%
+10,975
New +$22.7K
CASI
2744
DELISTED
CASI Pharmaceuticals
CASI
$22K ﹤0.01%
+1,224
New +$14.3K
STCN
2745
DELISTED
Steel Connect, Inc. Common Stock
STCN
$21K ﹤0.01%
1,205
-2
-0.2% -$30
VRML
2746
DELISTED
Vermillion, Inc.
VRML
$21K ﹤0.01%
11,837
+1,380
+13% +$2.03K
INSG icon
2747
Inseego
INSG
$120M
$20K ﹤0.01%
1,357
+59
+5% +$755
VKTX icon
2748
Viking Therapeutics
VKTX
$3.8B
$20K ﹤0.01%
+10,366
New +$11.8K
INFI
2749
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$20K ﹤0.01%
15,080
+2
+0% +$2
CWEN.A
2750
DELISTED
Clearway Energy Class A
CWEN.A
$19K ﹤0.01%
1,068
-24
-2% -$435

Similar funds

Guggenheim Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Guggenheim Capital held 2,932 positions worth $42.6B, up 13% from $37.8B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Guggenheim Capital deployed $3.68B of net new capital in Q3 2017, opening 107 new positions and adding to 1,463 existing holdings. Its largest new stake was CLAYMORE US CAPITAL MARKETS MICRO-TERM FIXED INCOME ETF: 1,677,943 shares worth $84.5M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 14% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $46.6M trimmed.

  • Guggenheim Capital's largest Q3 2017 buy was CLAYMORE US CAPITAL MARKETS MICRO-TERM FIXED INCOME ETF: 1,677,943 shares worth $84.5M.
  • Guggenheim Capital added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2017, an estimated $209M increase.
  • Guggenheim Capital's biggest Q3 2017 reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $46.6M.
  • Guggenheim Capital fully exited Reynolds American Inc in Q3 2017, selling an estimated $68.3M.
  • Guggenheim Capital's ten largest holdings make up 13% of its $42.6B portfolio in Q3 2017.
  • Guggenheim Capital opened 107 new positions and closed 134 in Q3 2017.
  • Guggenheim Capital's portfolio value rose 13% quarter-over-quarter to $42.6B.

Based on Guggenheim Capital's 13F filing for Q3 2017, filed 14 Nov 2017.